NanoBio Protect goes on sale in 4,400 CVS stores around the country.
“Wash your hands thoroughly, for twenty seconds…Don’t touch your face…Wear a face mask…Maintain social distance.”
Those are the four steps people around the world are following in an effort to prevent infections. “But studies show that no matter how hard they try, people touch their faces several times a minute, often without knowing it,” says Dr. Chad Costley, a primary care doctor. “I know whenever I take off my medical mask, the first thing I want to do is rub my nose.”
So, imagine if you could buy a product that kills 99.99% of germs, but is suitable for application to the skin in and around your nose?
Now you can.
BlueWillow Biologics, an Ann Arbor-based biopharmaceutical company, has just begun marketing NanoBioProtect, an FDA over-the-counter antiseptic solution that has proven to be effective in killing germs that can gain entry through the nose. Users dip a Q-tip into the solution, then gently swab it in and around the nostrils. The solution is alcohol-free, fragrance-free, and lasts at least four hours.
“This technology holds great promise for preventing devastating diseases,” Costley says. “For twenty years, we have been a science company, not a sales and marketing organization, but now we have an opportunity to make a significant difference in helping to protect our communities.” After a decade of involvement with BlueWillow, including serving on the board of directors, Costley was named the company’s chief medical officer in April. Although his home and practice are in Atlanta, he earned his undergraduate and medical degrees from U-M and served his residency here.
U-M professor Dr. James Baker spun the company (originally called NanoBio) off from U-M in 2000, with the goal to develop nano-scale dermatology applications. (A nano is defined as “one-billionth”, or the length a fingernail grows in a second.) In April, Costley was named chief medical officer for the 15-person organization.
For two decades, the company has partnered with the Gates Foundation, National Institutes of Health, and Department of Defense, to work on therapies and vaccines “focused on developing solutions to address global health problems.” NanoBio Protect is its first product to reach the market.
Originally, NanoBio Protect was developed in conjunction with the U.S. Department of Defense and the U-M, to develop a topical product to protect and treat wound infections. The active ingredient, BZK, is attached to oil nano-droplets. “The droplets carry the BZK to the surface of the germ and persist on the skin for a prolonged period,” Costley explains. “The formula holds the active ingredient suspended, so it doesn’t crystalize like many antiseptics will, which can lead to irritation. ” The solution is alcohol-free and soothing to the skin.
“Over the last five years, research indicated that this product was effective against a number of germs. When the COVID-19 pandemic began spreading, we strongly suspected it would be active against COVID-19 in lab testing, as well.” BlueWillow quickly partnered with Public Health England (PHE), to study the product’s anti-viral activity against the novel coronavirus. Because this virus is potentially lethal, tests were conducted in the most secure laboratory environments, Biosafety Level 3 facilities, at the PHE headquarters in England.
Scientists mixed the COVID-19 virus with the product, and samples were taken at various time intervals, then plated for viral counts. After five to seven days, the plates were fixed and stained, and the plaques were counted. The results were conclusive – NanoBio® Protect killed the COVID-19 virus at every time interval up to four hours. The product has not been tested in humans to prevent or treat any disease, including Covid-19.
“The results were exciting —but not surprising to us,” Costley adds. “It’s rewarding after so many years of research to have a product that people can use, a product that makes a difference. People have spent a lot of time and energy keeping their hands clean, but a nasal antiseptic seemed intuitive. We are providing a layer of protection at the nose area.”
BlueWillow has just put the product on the market, selling it through their website for $24.95 for an 18-ml bottle that, Costley says, should last a month with once-daily applications—“although people in contact with large numbers of people, like flight attendants, could use it three to four times a day.” NanoBio Protect will also be available on Amazon shortly. Meanwhile, the company is in the process of donating 40,000 bottles to hospitals and healthcare professionals around the country.
More than $190 million has been invested in developing BlueWillow’s nanotechnology platform. Before the pandemic, the company had been working—and continues to work—with PHE and the National Institutes of Health (NIH) on solutions for intranasal immunotherapy, particularly for food and respiratory allergies, among them peanut and milk allergies. A second division focuses on developing intranasal vaccines for respiratory and sexually transmitted infections. NanoVax, an intranasal anthrax vaccine, is in the first phase of human studies, but BlueWillow scientists are also working to develop intranasal vaccines for influenza, RSV, and HSV-2.
“Vaccine research is long and expensive and exciting,” Costley says. “Predicting the timing to get a vaccine to users is very difficult.”
When asked to predict when an effective COVID-19 vaccine might be available, he suggested, “Having a vaccine available by September would be unprecedented in terms of speed, but these are unprecedented times. Until a vaccine is readily available to the public, though, everyone should do everything they can to protect themselves.”
—
Note: An edited version of this article was published in the November 2020 publication of the Ann Arbor Observer.

